Compare · ICCM vs WST
ICCM vs WST
Side-by-side comparison of IceCure Medical Ltd. (ICCM) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ICCM and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $24.52B, about 3139.3x ICCM ($7.8M).
- Over the past year, ICCM is down 92.3% and WST is up 42.5% - WST leads by 134.8 points.
- ICCM has been more active in the news (22 items in the past 4 weeks vs 1 for WST).
- WST has more recent analyst coverage (18 ratings vs 2 for ICCM).
- Company
- IceCure Medical Ltd.
- West Pharmaceutical Services Inc.
- Price
- -
- -
- Market cap
- $7.8M
- $24.52B
- 1M return
- -22.77%
- +5.23%
- 1Y return
- -92.33%
- +42.52%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 22
- 1
- Recent ratings
- 2
- 18
IceCure Medical Ltd.
IceCure Medical Ltd develops and markets minimally invasive cryoablation therapies for women's health and oncology markets. It offers ProSense system, a cryoablation solution for breast tumors. The company was founded in 2006 and is headquartered in Caesarea, Israel.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest ICCM
- SEC Form 6-K filed by IceCure Medical Ltd.
- IceCure Signs Exclusive Distribution Agreement for ProSense® Cryoablation Systems in the Netherlands
- West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation
- SEC Form EFFECT filed by IceCure Medical Ltd.
- SEC Form EFFECT filed by IceCure Medical Ltd.
- VP, Sales for North America Good Shad was granted 131,483 units of Ordinary Shares, increasing direct ownership by 2,521% to 136,698 units (SEC Form 4)
- SEC Form 3 filed by new insider Salton David
- VP, BD & Global Marketing Tel-Tzure Tlalit Bussi was granted 101,483 units of Ordinary Shares, increasing direct ownership by 2,016% to 106,518 units (SEC Form 4)
- VP, Human Resources Dotan Merav Nir was granted 73,890 units of Ordinary Shares, increasing direct ownership by 3,244% to 76,168 units (SEC Form 4)
- SEC Form 4 filed by Director Chan Vincent Chun Hung
Latest WST
- SVP & Chief Financial Officer Mcmahon Robert W. converted options into 7,149 shares and covered exercise/tax liability with 3,109 shares, increasing direct ownership by 136% to 7,021 units (SEC Form 4)
- SEC Form 10-Q filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- West Declares Quarterly Dividend
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- BNP Paribas Exane initiated coverage on West Pharm with a new price target
- West to Host Second-Quarter 2026 Conference Call
- SEC Form 4 filed by Director Haugen Janet Brutschea
- West Completes Sale and Transfer of the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System
- West Pharm upgraded by Barclays with a new price target